The S1P receptor modulator etrasimod was more effective than placebo in two phase 3 trials and well tolerated in patients...
Read moreData from a phase 2 proof-of-concept study suggest that combination therapy with guselkumab and golimumab may be more effective for...
Read moreMetachronous cancers were not significantly associated with biopsy of non-tumor sites after biopsy of the primary cancer in this large...
Read moreIn a prospective cohort, there was an increased risk of incident AAEs and premature AAEs in IBD participants. Beyond traditional...
Read moreHospitalized patients with COVID-19 had fewer problems with constipation and hard stools at 12 months after acute COVID-19 infection. In...
Read morePost-hoc analysis of data from the SELECTION trial indicates that filgotinib therapy results in rapid and sustained improvements of symptoms...
Read moreA cohort study indicates that emergency colectomy rates have halved in the past 25 years to 8–15% worldwide. Patients not...
Read moreResults of a randomized trial of FMT after 2 and 3 years indicate that FMT results in high response rates...
Read moreIn this pilot trial involving 52 patients, the glucagon-like peptide 1 receptor agonist liraglutide was superior to colesevelam in reducing...
Read moreIn this phase 2b trial, all doses of ABX464 improved disease activity after 8 weeks significantly better than placebo.
Read more© 2024 JNews - Premium WordPress news & magazine theme by Jegtheme.
Si ya esta registrado ingrese aquí
Si ya esta registrado ingrese aquí